<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Nonalcoholic <z:hpo ids='HP_0001397'>fatty liver</z:hpo> disease (NAFLD) is closely related to <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, <z:hpo ids='HP_0001513'>obesity</z:hpo>, type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0001513'>Obesity</z:hpo> and <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> are associated with an increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk, and recent evidence demonstrated an association between NAFLD and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>The mechanism of how NAFLD can be associated with increased risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> is not fully understood; however, NAFLD represents a condition of profound <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and a proinflammatory state </plain></SENT>
<SENT sid="3" pm="."><plain>Insulin and insulin-like growth factors may promote the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> through their proliferative and antiapoptotic effects </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with NAFLD have reduced expression of adiponectin, an adipokine with anti-inflammatory effects </plain></SENT>
<SENT sid="5" pm="."><plain>Importantly, hypoadiponectinemia is associated with an increased risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Decreased levels of adiponectin lead to increased insulin levels due to marked <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and in turn increased insulin growth factor-1 (IGF-1) </plain></SENT>
<SENT sid="7" pm="."><plain>Insulin binds to IGF-1 receptors and plays an important role in cell proliferation, <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and increased production of vascular endothelial growth factor, an angiogenic factor that supports <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> growth </plain></SENT>
<SENT sid="8" pm="."><plain>Further studies are needed to establish (i) the pathophysiology of NAFLD with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, (ii) the benefit of early screening of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> in NAFLD patients, and (iii) the impact of treatment of NAFLD in the modulation of the risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>